IBRX270115C00015000
IBRX Jan 15 2027 15.00 Call
optionOPRA
EODOct 16, 2026
0.62USD-26.190%(-0.22)598Vol13,429OI
Loading…
Underlying
Underlying Price
$8.48
Type
Call
Strike
15
Expiration
Jan 15, 2027
DTE
87d
Moneyness
OTM
Intrinsic
$0.00
IBRX 15 Call Across Expirations
| Expiration | DTE | Last | Change | Vol | Open Int |
|---|---|---|---|---|---|
| Oct 23, 2026 | 3d | $0.95 | +1800.00% | 2 | 68 |
| Oct 30, 2026 | 10d | — | — | 0 | 0 |
| Nov 6, 2026 | 17d | $0.25 | +0.00% | 2 | 2 |
| Nov 13, 2026 | 24d | — | — | 0 | 0 |
| Nov 20, 2026 | 31d | $0.15 | -40.00% | 45 | 1,347 |
| Nov 27, 2026 | 38d | $0.35 | +0.00% | 41 | 41 |
| Dec 18, 2026 | 59d | — | — | 0 | 0 |
| Jan 15, 2027 | 87d | $0.62 | -26.19% | 598 | 13,429 |
| Mar 19, 2027 | 150d | $0.95 | -40.63% | 2 | 2,008 |
| Apr 16, 2027 | 178d | $1.10 | -43.59% | 1 | 48 |
| May 21, 2027 | 213d | $2.00 | +14.29% | 115 | 1,179 |
| Aug 20, 2027 | 304d | $1.71 | -24.67% | 33 | 39 |
| Nov 19, 2027 | 395d | $2.75 | -2.83% | 1 | 6 |
| Jan 21, 2028 | 458d | $2.80 | +3.70% | 53 | 7,866 |
| Mar 17, 2028 | 514d | $3.40 | +3.03% | 1 | 257 |
| Jan 19, 2029 | 822d | $3.65 | -8.29% | 2 | 167 |
IBRX Nearby Strikes · Jan 15, 2027
| Strike | Last | Change | Vol | Open Int | Moneyness |
|---|---|---|---|---|---|
| 9 C | $1.87 | -25.20% | 64 | 6,730 | OTM |
| 10 C | $1.55 | -26.19% | 2,280 | 72,137 | OTM |
| 11 C | $1.15 | -32.35% | 392 | 16,123 | OTM |
| 12 C | $1.00 | -31.03% | 717 | 10,602 | OTM |
| 13 C | $0.89 | -33.58% | 66 | 898 | OTM |
| 14 C | $1.00 | -16.67% | 10 | 3,110 | OTM |
| 15 C | $0.62 | -26.19% | 598 | 13,429 | OTM |
| 16 C | $0.52 | -36.59% | 1 | 2,413 | OTM |
| 17 C | $0.45 | -32.84% | 4 | 2,431 | OTM |
| 18 C | $0.20 | -67.74% | 3 | 28 | OTM |
| 20 C | $0.29 | -25.64% | 38 | 10,172 | OTM |
| 22 C | $0.25 | -3.85% | 35 | 7,812 | OTM |
IBRX Profile
immunitybio is a leading registration-stage immuno-oncology and infectious disease company activating both the innate (natural killer cell and macrophage) and adaptive (t cell) immune system. we are developing molecular and product platforms including n-803, aldoxorubicin, and a second-generation adenovirus vector, which are based upon our three key modalities of activating natural killer ('nk') and t cells, tumoricidal macrophages, and memory t cells.